David Ricks, Eli Lilly CEO (Al Drago/Bloomberg via Getty Images)
How the price of Lilly's weight management drug could fuel its rivalry with Novo Nordisk
Eli Lilly’s highly anticipated weight loss rival Zepbound is set to hit shelves this year at a steep discount to Novo Nordisk’s Wegovy and with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
